With Jozine ter Maaten, University Medical Center Groningen - The Netherlands, Antonio Cannata, King's College London - UK, Mateusz Sokolski, Wroclaw Medical University - Poland, Henrike Arfsten, Medical University of Vienna - Austria, Stefan Anker, Charité University Hospital Berlin - Germany, Muthiuh Vaduganathan, Brigham and Women's hospital, Harvard Medical School Boston - USA, Cornelia Margineanu, Bucharest – Romania and Kengo Kusano, National Cerebral and Cardiovascular Center Hospital, Osaka - Japan.

In this multivoice podcast from the ESC Congress 2024, the main results of three randomized controlled clinical trials (FINEARTS-HF, RESHAPE-HF2, and CRABL-HF) are discussed.

Links to the papers:

FINEARTS-HF

RESHAPE-HF2

This 2024 HFA CardioTalk podcast serie is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

With Guillaume Baudry, University Hospital of Brabois, Nancy - France, and Marco Metra, University of Brescia - Italy.

In this episode of the HFA Cardiotalk podcast, Guillaume Baudry interviews Marco Metra, the lead author of the recent HFA clinical consensus statement on worsening heart failure. They delve into the definition of worsening heart failure, its prognosis, prevention strategies, and both acute and long-term management of this condition.

Related scientific paper:

• Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology
• Risk of readmission and death after hospitalization for worsening heart failure: Role of post-discharge follow-up visits in a real-world study from the Grand Est Region of France
• Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
• Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
• Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
• Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial
• Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

This 2024 HFA CardioTalk podcast serie is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

With Raja Ezman Faridz Bin Raja Shariff, Universiti Teknologi MARA, Selangor - Malaysia, and Kevin Damman, University Medical Centre Groningen - The Netherlands

In this episode of the HFA Cardiotalk podcast, Ezman Shariff interviewed Kevin Damman – a key opinion leader in the field of cardiorenal interactions, to better understand the role natriuresis plays in the acute heart failure and what we have learnt from trials like PUSH-AHF and ENACT-HF, and the future direction of clinical trials in this field.

This 2024 HFA CardioTalk podcast serie is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

With Jozine ter Maaten, University Medical Center Groningen, Groningen - the Netherlands, Marta Cobo Marcos, Hospital Puerta de Hierro, Madrid - Spain, Mateusz Sokolski, Wroclaw Medical University, Wroclaw, Poland, Aferdita Spahillari, Duke University Hospital, Durham, NC - USA, Laura Cohen, Massachusets General Hospital, Boston, MA - USA, Antonio Cannata, King's College London, London - United Kingdom & Varun Sundaram, Case Western Reserve University, Cleveland, OH, USA

This podcast discusses the results of four late-breaking clinical trials presented at the Heart Failure Congress 2024 in Lisbon, Portugal. First, Dr Cobo Marcos shares the results of the SALT-HF study, a randomised trial investigating the addition of hypertonic saline to diuretics in patients with worsening heart failure. Second, Dr Spahillari and Dr Cohen discuss the main findings and echo substudy of the TEAM-HF trial. Thirdly, Dr Sundaram gives us an insight into the results of the PRAISE-HFpEF trial. The podcast concludes with a brief discussion of some of the HFA Young highlights from the congress.

This 2024 HFA CardioTalk podcast series is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

With Jozine M. ter Maaten, University Medical Centre Groningen, Groningen - Netherlands, Bart A. Mulder, 2022-2024, University Medical Centre Groningen, Groningen - Netherlands & Giuseppe Boriani, Polyclinic Modena University Hospital, Modena -Italy.

Atrial fibrillation and heart failure often co-exist and influence each other. Treatment of AF specifically in the setting of heart failure can be challenging. Recently, new data emerged regarding the potential role of AF ablation in heart failure patients. In this podcast we discuss these in a special episode with a strong representation also from the EHRA Young highlighting the importance of interdisciplinary decision making in these patients.

Recommended readings from this episode:

CASTLE HTx

CASTLE AF

CABANA results in heart failure patients

This 2024 HFA CardioTalk podcast series is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

With Cornelia Margineanu, Bucharest - Romania & Thomas Felix Luscher, London - UK

A brief description of the discussion, which I have provided below: "In this episode, Dr. Cornelia Margineanu interviews Professor Thomas F. Lüscher on Education and professional development of the future generation of heart failure specialists, covering the entire pathway for young physicians, from training and having the right mentors to future trajectories.

"This 2024 HFA CardioTalk podcast series is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor."

With Mateusz Sokolski, Wroclaw Medical University, Wroclaw - Poland & Amina Rakisheva, Scientific Research Institute of Cardiology and Internal Diseases, Almaty - Kazakhstan.

Might heart failure be reversible or does it go only into remission in some cases? During this podcast, we discuss these issues, exploring the possibility of reversing heart failure and ending with regenerative medicine.

"This 2024 HFA CardioTalk podcast series is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor."

With Alberto Esteban-Fernández. Severo Ochoa University Hospital, Madrid - Spain & John McMurray. BHF Glasgow Cardiovascular Research Centre, Glasgow - UK.

We discuss the implementation of 2021 HF guidelines, the possibility of implementing foundational therapy in clinical practice, and difficulties and barriers. Also, we discuss future heart failure treatments in the coming years.
Access the 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.

"This 2024 HFA CardioTalk podcast series is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor."